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MaOBJECTIVES This analysis reports on the initial German multicenter experience with the JenaValve (JenaValve
Technology GmbH, Munich, Germany) transcatheter heart valve for the treatment of pure aortic regurgitation.
BACKGROUND Experience with transcatheter aortic valve implantation (TAVI) for severe aortic regurgitation is limited
due to the risk of insufﬁcient anchoring of the valve stent within the noncalciﬁed aortic annulus.
METHODS Transapical TAVI with a JenaValve for the treatment of severe aortic regurgitation was performed in
31 patients (age 73.8  9.1 years) in 9 German centers. All patients were considered high risk for surgery (logistic
EuroSCORE [European System for Cardiac Operative Risk Evaluation] 23.6  14.5%) according to a local heart team
consensus. Procedural results and clinical outcomes up to 6 months were analyzed.
RESULTS Implantation was successful in 30 of 31 cases (aortic annulus diameter 24.7  1.5 mm); transcatheter heart
valve dislodgement necessitated valve-in-valve implantation in 1 patient. Post-procedural aortic regurgitation was none/
trace in 28 of 31 and mild in 3 of 31 patients. During follow-up, 2 patients underwent valvular reinterventions (surgical
aortic valve replacement for endocarditis, valve-in-valve implantation for increasing paravalvular regurgitation).
All-cause mortality was 12.9% and 19.3% at 30 days and 6 months, respectively. In the remaining patients, a signiﬁcant
improvement in New York Heart Association class was observed and persisted up to 6 months after TAVI.
CONCLUSIONS Aortic regurgitation remains a challenging pathology for TAVI. After initial demonstration of feasibility,
this multicenter study revealed the JenaValve transcatheter heart valve as a reasonable option in this subset of patients.
However, a signiﬁcant early noncardiac mortality related to the high-risk population emphasizes the need for careful
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1169AB BR E V I A T I O N S
AND ACRONYM S
TAVI = transcatheter aortic
valve implantation
THV = transcatheter heart
valve
VARC = Valve Academic
arch ConsortiumA fter demonstration of efﬁcacy and safetythrough randomized trials (1,2), transcatheteraortic valve implantation (TAVI) has evolved
as the standard of care for the treatment of severe
aortic stenosis in patients considered inoperable or as
an alternative to surgery in patients at high operative
risk (3). However, predominant aortic regurgitation re-
mains a relative contraindication for TAVI according to
recent recommendations (3,4) due to the risk of insuf-
ﬁcient anchoring of the transcatheter heart valve
(THV) within the noncalciﬁed aortic annulus. Surgical
valve replacement remains the treatment of choice in
these patients (3), but alternatives are required if
they are considered to be at high surgical risk. Off-
label uses of the self-expanding Medtronic CoreValve
(Medtronic, Minneapolis, Minnesota) or the balloon-
expandable Edwards Sapien XT (Edwards Lifescien-
ces, Irvine, California) THV have been reported for
the treatment of aortic regurgitation (5,6), but limita-
tions have included a high rate of valve-in-valve im-
plantations related to residual aortic regurgitation or
the need for signiﬁcant oversizing and a subsequent
risk for annular rupture.
Recently, several strategies have been developed to
provide a transcatheter platform for the sufﬁcient
treatment of pure aortic regurgitation. This includes
the Helio system (Edwards Lifesciences), featuring
a pre-placed dock facilitating implantation of a
commercially available Sapien XT (7). The native aortic
valve cusps are captured between the dock and the
THV for sufﬁcient anchoring and the device is
currently under clinical investigation. With the CE-
mark (Conformité Européenne) approval of the
JenaValve (JenaValve Technology GmbH, Munich,
Germany) and Medtronic Engager systems for the
treatment of aortic stenosis, new devices have become
available that, in addition to their intended uses, may
facilitate the treatment of diseased noncalciﬁed valves
through their unique anchoring mechanisms. The
JenaValve prosthesis features a clip ﬁxation of the
native aortic valve cusps (8), offering secure anchorage
of the THV even in the absence of calciﬁcations. First
reports have demonstrated feasibility and successful
treatment of aortic regurgitation using the JenaValve
(9–11). We now report on the initial German multi-
center experience with implantation of a JenaValve
THV for the treatment of pure aortic regurgitation in
patients at high risk for surgery.
METHODS
PATIENT POPULATION AND DIAGNOSTIC WORKUP.
From April 12, 2012 through October 10, 2013,
SEE PAGE 117531 patients were treated for pure aortic
regurgitation using the JenaValve THV in 9
German centers (as listed in Online Table 1);
early results on 5 of these patients were
published before (9). All patients presented
with severe comorbidities precluding them
from surgical aortic valve replacement as
determined by an interdisciplinary heart
team (Table 1). Pre-procedural workup was completed
according to institutional standards. Evaluation and
grading of aortic regurgitation at baseline was per-
formed by transesophageal echocardiography in all
patients (12). Aortic annulus, root, and valve mor-
phology were assessed by contrast-enhanced multi-
slice computed tomography (n ¼ 20), transesophageal
echocardiography (n ¼ 11), or the combination of
both techniques (Figure 1). Effective aortic annulus
diameters for sizing of the THV were derived
from multiplanar reconstruction of computed tomog-
raphy data or from the mid-esophageal long-axis view
in transesophageal echocardiography. All patients
presented with pure moderate (n ¼ 1) or severe
(n ¼ 30) aortic regurgitation. Any patients with
mixed valve disease or previous aortic valve replace-
ment were excluded from the study. Aortic valve
calcium was assessed by computed tomography or
transesophageal echocardiography, as previously
described (13).
PROCEDURAL ASPECTS. Transapical implantation
of the JenaValve was performed under general
anesthesia by an interdisciplinary heart team as
previously described (8,9). Balloon valvuloplasty of
the native aortic valve was omitted, except in 1
patient with partial commissural fusion. Valve size
was selected according to the manufacturer’s rec-
ommendations in 27 of 31 patients. Hence, a 23-mm
THV was chosen for an aortic annulus up to
22.9 mm, a 25-mm prosthesis for an aortic annulus
from 23 to 24.9 mm, and a 27-mm JenaValve for
an aortic annulus from 25 to 27 mm. Excessive
oversizing was performed in 4 of 31 patients
(27-mm THV in 3 patients with annulus diameters
23 to 24 mm, 25-mm THV in 1 patient with an
annulus diameter of 22 mm). Of note, only echo-
cardiographic annulus measurements were available
in these 4 patients. Anatomically oriented implan-
tation of the JenaValve prosthesis was performed
without the use of rapid ventricular pacing in
most cases under ﬂuoroscopic control, as de-
tailed in Figure 2. Evaluation of valve function
and quantiﬁcation of residual aortic regurgita-
tion after TAVI was performed by transesophageal
echocardiography and angiography in 26 of 31
and by transthoracic echocardiography in 5 of
Rese
TABLE 1 Baseline Clinical Parameters
n 31
Age, yrs 73.8  9.1
Female 11 (35.5)
BMI, kg/m2 24.0  4.5
Systemic hypertension 26 (83.9)
Diabetes mellitus 4 (12.9)
Peripheral vascular disease 6 (19.3)
Cerebrovascular disease 6 (19.3)
Previous stroke 7 (22.6)
Atrial ﬁbrillation 6 (19.3)
Previous permanent pacemaker implantation 3 (9.7)
Chronic lung disease 9 (29.0)
Serum creatinine, mg/dl 1.3  0.5
Anemia 20/30 (66.7)
Coronary artery disease 20 (64.5)
Previous myocardial infarction 11 (35.5)
Previous percutaneous coronary intervention 10 (32.2)
Previous coronary artery bypass graft 7 (22.6)
Previous valve surgery* 6 (19.3)
NYHA functional class >III 12 (38.7)
Ascending aortic diameter, mm† 36.6  7.0 (20/31)
Aortic regurgitation mode
Annular dilation 6 (19.3)
Degenerative 15 (48.4)
Post-endocarditis 4 (12.9)
Rheumatic 1 (3.2)
Post-radiation therapy 1 (3.2)
Unknown 4 (12.9)
Aortic regurgitation grade
None or mild 0
Moderate 1 (3.2)
Severe 30 (96.8)
Pulmonary artery pressure >55 mm Hg 6/30 (20.0)
Mitral regurgitation $moderate 8 (25.8)
Left ventricular ejection fraction, % 46.8  16.1
Logistic EuroSCORE I, % 23.6  14.5
Logistic EuroSCORE II, % 9.3  6.4
STS-PROM, % 5.4  3.6
Values are n, mean  SD, n (%), n/N (%), or mean  SD (n/n). *Previous valve
surgery included mitral valve surgery (n ¼ 3) and aortic valve repair (n ¼ 3).
†Ascending aorta diameters were assessed by multislice computed tomography or
transesophageal echocardiography.
BMI ¼ body mass index; EuroSCORE ¼ European System for Cardiac Operative
Risk Evaluation; NYHA ¼ New York Heart Association; STS-PROM ¼ Society of
Thoracic Surgeons Predicted Risk of Mortality.
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(14).
Combined procedureswere performed in 4 patients,
including concomitant MitraClip (Abbott Vascular,
Santa Clara, California) implantation for severe mitral
regurgitation (n ¼ 2), occlusion of paravalvular regur-
gitation after previous mechanical mitral valve
replacement (n ¼ 1), and implantation of a left
ventricular assist device for severe ischemic cardio-
myopathy (n ¼ 1) (HeartWare, Framingham, Massa-
chusetts). Transcatheter treatment formoderate aorticregurgitation in this patient was performed in antici-
pation of deteriorating regurgitation during left
ventricular assistance and the presence of a porcelain
aorta precluding surgical valve replacement.
DATA MANAGEMENT AND FOLLOW-UP. This anal-
ysis was designed as an independent voluntary
multicenter analysis of patients treated for aortic
regurgitation using the JenaValve THV. All relevant
baseline, procedural, and follow-up variables were
collected retrospectively from 9 German centers
in a dedicated database. The authors take full re-
sponsibility for the data integrity. Median clinical
follow-up duration was 235 days (interquartile range
160, 351 days). Outcomes were analyzed in accor-
dance with the updated standardized endpoints
deﬁned by the Valve Academic Research Consortium
(VARC) (14).
ETHICS. All patients were fully informed about the
procedure and this off-label use of the THV (at the
time of implantation). All patients signed written
consent forms.
RESULTS
BASELINE CHARACTERISTICS. Overall, 31 patients
(mean age 73.8  9.1 years, 35.5% female) presented
with pure aortic regurgitation and high surgical risk,
as listed in Table 1. The etiology of regurgitation was
degenerative in the majority of patients but also
included annular dilation, previous endocarditis, and
rheumatic or post-radiation valve disease. No aortic
valve calcium was detected in the majority of patients
(24 of 31), whereas 7 patients were considered to have
mild valve calciﬁcation (small isolated spots) without
any signs of valve stenosis. All patients were symp-
tomatic with 28 of 31 in New York Heart Association
functional class III or IV; 11 patients had undergone
previous sternotomy for coronary artery bypass or
valve surgery.
PROCEDURAL OUTCOMES. TAVI using the Jena-
Valve second-generation THV was performed suc-
cessfully in 30 of 31 procedures (Table 2). Due to
incomplete capture of the native aortic valve cusps,
dislodgment, and subsequent relevant regurgita-
tion, immediate valve-in-valve implantation of an
Edwards Sapien XT prosthesis was performed in 1
patient with good ﬁnal results. A horizontal aorta
complicated alignment and implantation in another
patient; despite post-dilation, mild paravalvular
regurgitation remained. Extracorporeal circulatory
support or conversion to surgical valve replacement
was not required in any of the patients. Final hemo-
dynamic results conﬁrmed none or trace paravalvular
FIGURE 1 Aortic Annulus, Root, and Valve Morphology Assessed by Contrast-
Enhanced MSCT and TEE
Multiplanar reconstruction of baseline computed tomography in axial (A) and coronal (B)
views for assessment of aortic valve morphology and annular measurements. Three-
dimensional color Doppler evaluation conﬁrming severe aortic regurgitation before
transcatheter aortic valve implantation (C). MSCT ¼ multislice computed tomography;
TEE ¼ transesophageal echocardiography.
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1171regurgitation in 28 of 31 patients. No more than mild
regurgitation or signs of aortic stenosis were
observed (Figure 3A).
30-DAY CLINICAL OUTCOMES. According to
the VARC-2 criteria (Table 3), major access site com-
plications and subsequent bleeding events occurred
in 3 patients, including a retroperitoneal hematoma
with hemorrhagic shock, pericardial effusion re-
quiring pericardiocentesis, and hemothorax necessi-
tating surgical revision. Overall, 7 patients suffered
from acute kidney injury, with n ¼ 1 (3.2%)
classiﬁed as stage 3 acute kidney injury. No cerebro-
vascular events or myocardial infarctions occurred
during 30-day follow-up. Two patients underwent
permanent pacemaker implantation for persistent
sinus bradycardia (n ¼ 1) and complete heart block
(n ¼ 1). Thirty-day mortality was noncardiac in 3 pa-
tients (acute renal failure [day 10], pneumonia [day
13], sepsis [day 17]) and cardiac in 1 patient (severe
mitral regurgitation [day 7]). The VARC-deﬁned
composite endpoints device success and early safety
endpoint were reached in 96.8% and 19.3% of pa-
tients, respectively.
SIX-MONTH CLINICAL OUTCOMES. Valve reinter-
ventions were performed in 2 patients. Despite a
primarily uneventful post-operative course, 1 patient
showed increasing transvalvular gradients and mod-
erate regurgitation at 3-month follow-up. Fluoros-
copy suggested incomplete stent expansion due to an
isolated calcium spot at the aortic annulus. After
unsuccessful post-dilation of the JenaValve, valve-in-
valve implantation with an Edwards Sapien XT was
performed with a good result and no residual regur-
gitation. Clinical follow-up was uneventful there-
after. Another patient required surgical aortic valve
replacement due to endocarditis with subsequent
severe aortic regurgitation 5 months after compli-
cated TAVI with intraprocedural valve-in-valve
implantation.
Overall, residual aortic regurgitation remained low
throughout follow-up with 78.2% of patients with
none or trace aortic regurgitation at 6 months
(Figure 3B). New York Heart Association functional
classiﬁcation improved with 73.3% of patients in
class I or II at 30 days compared with 6.7% at baseline
and persisted up to 6 months (Figure 3C). Mortality at
6 months was 19.3%, including 2 more noncardiac
deaths.
DISCUSSION
According to the Euro Heart Survey (15), 10.4% of
patients with native valve disease suffer fromisolated aortic regurgitation. In contrast to elderly
patients with calciﬁc aortic stenosis, most of these
patients are good surgical candidates with a low
perioperative morbidity and mortality. Hence, aortic
valve surgery is the standard of care in patients
with severe aortic regurgitation and subsequent
symptoms or impaired left ventricular function (3).
However, therapeutic options in high-risk surgical
candidates are scarce because noncalciﬁed or pre-
dominant aortic regurgitation has been considered
a contraindication to TAVI (3,4). This caution is
attributed to imminent limitations of self-expanding
or balloon-expandable ﬁrst-generation THV, largely
relying on calciﬁcation of the native leaﬂets for
sufﬁcient anchoring of the expanded prosthesis.
Absent or minimal calciﬁcation of native aortic
cusps in pure aortic regurgitation result in the risk
of insufﬁcient anchoring and valve embolization
or residual paravalvular regurgitation. Excessive
oversizing carries a subsequent hazard for aortic
root rupture or incomplete valve expansion. In a
TABLE 2 Procedural Variables
Aortic annulus diameter, mm 24.7  1.5 (20.8–27.0)
THV size, mm
23 4 (12.9)
25 7 (22.6)
27 20 (64.5)
Procedure time, min 94.0  34.9
Fluoroscopy time, min 9.9  4.9
Contrast agent, ml 143.8  87.3
Valvuloplasty 1 (3.2)
Successful implantation 30 (96.8)
Post-dilation 2 (6.4)
Valve-in-valve 1 (3.2)
Conversion to SAVR 0
Coronary obstruction 0
Annulus rupture 0
Paravalvular aortic regurgitation
None 20 (64.5)
Trace 8 (25.8)
Mild 3 (9.7)
Moderate or severe 0
Mean aortic valve gradient, mm Hg 7.9  4.0 (26/31)
Values are mean  SD (range), n (%), or mean  SD.
SAVR ¼ surgical aortic valve replacement; THV ¼ transcatheter heart valve.
FIGURE 2 JenaValve THV Prosthesis
The JenaValve transcatheter heart valve (THV) prosthesis (JenaValve Technology GmbH, Munich, Germany), a trileaﬂet porcine root
tissue valve attached to a nitinol stent (A) and its implantation in illustration (B to D) and ﬂuoroscopy (E to H). Release of the posi-
tioning feelers and placement into the aortic sinuses enables anatomic orientation (B and F). After correct orientation has been veriﬁed
in 2 different ﬂuoroscopic angulations, release of the lower stent part facilitates the clipping of the native aortic valve leaﬂets to
the device and expansion of the stent allowing for secure anchoring even in the absence of valve calcium (C and G). Release of the
upper stent part completes deployment of the valve prosthesis (D and H). A to D are reprinted with permission from JenaValve
Technology GmbH.
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1172recently published multicenter series, Roy et al. (5)
report on the outcome of 43 patients undergoing
implantation of a CoreValve THV for pure aortic
regurgitation. Residual aortic regurgitation required
implantation of a second valve in 8 patients and
conversion to open heart surgery in 1. These com-
plications became particularly apparent in patients
with noncalciﬁed valve disease, emphasizing the
urgent need for alternative treatment options in
these patients.
In addition to safety and efﬁcacy in patients
with aortic stenosis (16,17), the JenaValve THV has
demonstrated promising results regarding the
treatment of aortic regurgitation (9–11). Successful
implantation and good hemodynamic performance
in patients with pure aortic regurgitation has now
been conﬁrmed at a larger scale in this multicenter
series. Six-month follow-up was promising with re-
gard to valve function. VARC-2 device success was
achieved in 30 of 31 patients and reduction of aortic
regurgitation to trace or none in 28 of 31 patients.
The feeler-guided positioning and secure clip ﬁxa-
tion mechanism of the native aortic valve cusps
allows for anatomically oriented implantation in
FIGURE 3 AR and NYHA Functional Class After TAVI
Aortic regurgitation (AR) before and residual paravalvular regurgitation after implantation
of the JenaValve transcatheter heart valve (THV) in all patients (n ¼ 31) (A) and in patients
with serial echocardiography up to 6 months (n ¼ 23) (B). New York Heart Association
(NYHA) functional classiﬁcation at baseline, 30 days, and 6 months (serial data, n ¼ 30)
(C). TAVI ¼ transcatheter aortic valve implantation.
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1173noncalciﬁed aortic valves, making it particularly
suitable for patients with predominant or pure
aortic regurgitation. However, optimal alignment is
required and may be complicated by a difﬁcult
anatomy (e.g., horizontal aorta) or insufﬁcient im-
aging that is mandatory for the precise placement of
the feelers within all 3 aortic sinuses for secure
anchoring of the valve stent. Inadequate align-
ment and suboptimal positioning of the THV
may render relevant residual regurgitation or—at
worst—dislodgment of the prosthesis. Although
rare in pure aortic regurgitation, inhomogeneous
calciﬁcation patterns may not be ideal for the
JenaValve THV, which carries less radial force
than a balloon-expandable THV does. This was
observed in 1 patient with incomplete stent expan-
sion yielding valve-in-valve implantation at a later
date. Hence, regular follow-up remains essential
in this young phase of experience to detect
potential shortcomings or complications at an early
stage.
Despite uncomplicated procedures and unevent-
ful post-procedural courses in the majority of
patients, 30-day and 6-month noncardiac mortality
was signiﬁcant in this series. Adequate function
of the implanted prosthesis was conﬁrmed in all
of these patients. However, adverse events linked
to underlying comorbidities emphasize the impor-
tance of adequate patient selection and optimal
timing of the procedure in order to improve overall
survival.
Several aspects may render patients with aortic
regurgitation particularly suitable for the des-
cribed transcatheter approach. The absence of aortic
valve calcium and a rare need for valvuloplasty may
potentially lower the risk for thromboembolic
events. Although possibly an effect of the small
sample size, no cerebrovascular events were detec-
ted in this study. In addition, the omission of
oversizing, the low radial force of the JenaValve
and the rare need for valvuloplasty or post-dilation
may alleviate the risk for conduction disturbances
and annular dilation or rupture after TAVI in pa-
tients with noncalciﬁed aortic annuli. Rapid ven-
tricular pacing is not required for optimal alignment
and stabilization during valve deployment and
most procedures can be performed with a beating
heart. Particularly in patients with poor left ven-
tricular function this may add safety to the
procedure.
STUDY LIMITATIONS. Limitations of this voluntary
multicenter analysis include its retrospective
character and the lack of an echocardiographycore laboratory or an independent event adjudi-
cation committee. Follow-up was limited to
6 months and further follow-up now needs
to conﬁrm persistent valve function in these
TABLE 3 VARC-2 Deﬁned Endpoints
Myocardial infarction 0
Cerebrovascular event 0
Bleeding, major or life-threatening 3 (9.7)
Access site complication
Minor 1 (3.2)
Major 3 (9.7)
Acute kidney injury
Stage 1 or 2 6 (19.3)
Stage 3 1 (3.2)
Permanent pacemaker implantation 2 (6.4)*
ICU stay, days 3.2  2.8
In-hospital stay, days 10.8  5.6
Device success 30 (96.8)
Combined early safety endpoint, 30 days 6 (19.3)
All-cause mortality, 30 days 4 (12.9)
Cardiac mortality, 30 days 1 (3.2)
All-cause mortality, 6 months 6 (19.3)
Cardiac mortality, 6 months 1 (3.2)
Values are n, n (%), or mean  SD. Thirty-day patient outcomes according to the
updated Valve Academic Research Consortium deﬁnitions (14). *Permanent
pacemaker implantation for persistent sinus bradycardia (n ¼ 1) and complete
heart block (n ¼ 1).
ICU ¼ intensive care unit; VARC ¼ Valve Academic Research Consortium.
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1174patients with noncalciﬁed aortic valves over the
long term, particularly before moving toward
younger or intermediate risk patients. After the
recent CE-mark approval for this new indication inSeptember 2013, patients with pure aortic re-
gurgitation are being prospectively included in
the currently recruiting JUPITER (Longterm
Safety and Performance of the JenaValve) registry
(NCT01598844).CONCLUSIONS
Pure aortic regurgitation remains a challenging
pathology for TAVI. After initial demonstration of
feasibility, this multicenter experience provides
broader evidence that the JenaValve THV is an
adequate option in these speciﬁc patients due to its
unique stent design and ﬁxation mechanism. The
straightforward implantation technique and good
acute results have recently established aortic
regurgitation as a new indication for this device.
Continued observation is now warranted to con-
ﬁrm persistent valve function during long-term
follow-up.
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